KR102622656B1 - 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 - Google Patents

5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 Download PDF

Info

Publication number
KR102622656B1
KR102622656B1 KR1020187022959A KR20187022959A KR102622656B1 KR 102622656 B1 KR102622656 B1 KR 102622656B1 KR 1020187022959 A KR1020187022959 A KR 1020187022959A KR 20187022959 A KR20187022959 A KR 20187022959A KR 102622656 B1 KR102622656 B1 KR 102622656B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
adpr
adenovirus
condition
keratitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187022959A
Other languages
English (en)
Korean (ko)
Other versions
KR20180111841A (ko
Inventor
로버트 쉘비츠
Original Assignee
인버사, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인버사, 인크. filed Critical 인버사, 인크.
Priority to KR1020237034890A priority Critical patent/KR102883682B1/ko
Publication of KR20180111841A publication Critical patent/KR20180111841A/ko
Application granted granted Critical
Publication of KR102622656B1 publication Critical patent/KR102622656B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
KR1020187022959A 2016-02-18 2017-02-17 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 Active KR102622656B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237034890A KR102883682B1 (ko) 2016-02-18 2017-02-17 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662296665P 2016-02-18 2016-02-18
US62/296,665 2016-02-18
US201662428721P 2016-12-01 2016-12-01
US62/428,721 2016-12-01
PCT/US2017/018253 WO2017143113A1 (en) 2016-02-18 2017-02-17 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034890A Division KR102883682B1 (ko) 2016-02-18 2017-02-17 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법

Publications (2)

Publication Number Publication Date
KR20180111841A KR20180111841A (ko) 2018-10-11
KR102622656B1 true KR102622656B1 (ko) 2024-01-10

Family

ID=58191671

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187022959A Active KR102622656B1 (ko) 2016-02-18 2017-02-17 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
KR1020237034890A Active KR102883682B1 (ko) 2016-02-18 2017-02-17 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237034890A Active KR102883682B1 (ko) 2016-02-18 2017-02-17 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법

Country Status (16)

Country Link
US (3) US11110112B2 (https=)
EP (2) EP3416654B1 (https=)
JP (4) JP6946353B2 (https=)
KR (2) KR102622656B1 (https=)
CN (2) CN108601793B (https=)
AU (2) AU2017219878B2 (https=)
BR (1) BR112018016398A2 (https=)
DK (1) DK3416654T3 (https=)
ES (1) ES2900524T3 (https=)
HR (1) HRP20211942T1 (https=)
HU (1) HUE057052T2 (https=)
IL (2) IL291574B2 (https=)
LT (1) LT3416654T (https=)
PL (1) PL3416654T3 (https=)
PT (1) PT3416654T (https=)
WO (1) WO2017143113A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230148389A (ko) * 2016-02-18 2023-10-24 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191026A2 (en) * 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
KR102789553B1 (ko) * 2021-09-07 2025-04-03 주식회사 펄스인마이어스 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
EP4509133A4 (en) * 2023-03-02 2026-03-25 Pearlsinmires Co Ltd ADP-RIBOSE BINDING PEPTIDE FOR CANCER PREVENTION OR TREATMENT, AND ADP-RIBOSE POLYTHERAPY
WO2026073064A1 (en) * 2024-09-30 2026-04-02 Invirsa, Inc. 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099297A1 (en) * 2002-05-21 2003-12-04 Abbott Laboratories Treatment of mucositis
WO2005123030A1 (en) 2004-06-15 2005-12-29 Abbott Laboratories Topical compositions containing 5'-adenosine-diphosphate ribose

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (ja) 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
JP2001515916A (ja) * 1997-09-11 2001-09-25 オクシジェン，インコーポレイテッド 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法
WO2000050024A2 (en) 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
EP1192258A2 (en) 1999-06-16 2002-04-03 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
EP1409503A1 (en) 2001-07-25 2004-04-21 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1948215B1 (en) 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
WO2008154129A1 (en) 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
JP2013526514A (ja) 2010-05-10 2013-06-24 ラディカル・セラピューティックス・インコーポレイテッド リポ酸およびニトロキシド誘導体およびその使用
KR101967938B1 (ko) 2011-05-12 2019-04-10 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물
US20160287622A1 (en) 2013-11-18 2016-10-06 Massachusetts Institute Of Technology Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099297A1 (en) * 2002-05-21 2003-12-04 Abbott Laboratories Treatment of mucositis
WO2005123030A1 (en) 2004-06-15 2005-12-29 Abbott Laboratories Topical compositions containing 5'-adenosine-diphosphate ribose

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230148389A (ko) * 2016-02-18 2023-10-24 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
KR102883682B1 (ko) * 2016-02-18 2025-11-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법

Also Published As

Publication number Publication date
IL291574A (en) 2022-05-01
AU2017219878B2 (en) 2022-12-22
JP2025032189A (ja) 2025-03-11
US20220054522A1 (en) 2022-02-24
IL291574B1 (en) 2025-01-01
IL291574B2 (en) 2025-05-01
KR20230148389A (ko) 2023-10-24
IL261095B (en) 2022-04-01
JP7222042B2 (ja) 2023-02-14
JP2021193126A (ja) 2021-12-23
US11110112B2 (en) 2021-09-07
US20200330498A1 (en) 2020-10-22
CN108601793A (zh) 2018-09-28
AU2023201678B2 (en) 2025-03-13
KR102883682B1 (ko) 2025-11-10
LT3416654T (lt) 2022-01-10
JP6946353B2 (ja) 2021-10-06
JP2023055858A (ja) 2023-04-18
BR112018016398A2 (pt) 2018-12-18
ES2900524T3 (es) 2022-03-17
US12370209B2 (en) 2025-07-29
US20240091249A1 (en) 2024-03-21
US11857561B2 (en) 2024-01-02
CA3014071A1 (en) 2017-08-24
EP3978003A1 (en) 2022-04-06
HRP20211942T1 (hr) 2022-03-18
JP2019505596A (ja) 2019-02-28
JP7600282B2 (ja) 2024-12-16
HUE057052T2 (hu) 2022-04-28
AU2017219878A1 (en) 2018-08-09
EP3416654A1 (en) 2018-12-26
DK3416654T3 (da) 2021-12-13
AU2023201678A1 (en) 2023-04-13
CN117482102A (zh) 2024-02-02
IL261095A (en) 2018-10-31
EP3416654B1 (en) 2021-10-27
CN108601793B (zh) 2024-08-23
PL3416654T3 (pl) 2022-03-21
PT3416654T (pt) 2021-12-22
WO2017143113A1 (en) 2017-08-24
KR20180111841A (ko) 2018-10-11

Similar Documents

Publication Publication Date Title
JP7600282B2 (ja) ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2021519315A (ja) ５’−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
HK1249443A1 (en) Depot preparation containing citric acid ester
WO2025122455A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr) for vegf modulation
US10940144B2 (en) Drug containing pyridylaminoacetic acid compound
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40073052A (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
US9504691B2 (en) Finafloxacin suspension compositions
HK1263210B (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
JP2004331502A (ja) 視神経細胞保護剤
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601